Principles Governing A-to-I RNA Editing in the Breast Cancer Transcriptome

Cell Reports

Volumn 13, Issue 2, 2015, Pages 277-289

  Fumagalli, Debora ^a   Gacquer, David ^b   Rothé, Françoise ^a   Lefort, Anne ^b   Libert, Frederick ^b   Brown, David ^a   Kheddoumi, Naima ^a   Shlien, Adam ^d   Konopka, Tomasz ^b   Salgado, Roberto ^a   Larsimont, Denis ^a   Polyak, Kornelia ^e   Willard Gallo, Karen ^a   Desmedt, Christine ^a   Piccart, Martine ^a   Abramowicz, Marc ^f   Campbell, Peter J ^d   Sotiriou, Christos ^a   Detours, Vincent ^b,c  

^a JULES BORDET INSTITUTE   (Belgium)

^b UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

^c WELBIO   (Belgium)

^d WELLCOME TRUST SANGER INSTITUTE   (United Kingdom)

^e DANA FARBER CANCER INSTITUTE   (United States)

^f ERASME HOSPITAL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE DEAMINASE; ADENOSINE DEAMINASE THAT ACT ON RNA; INTERFERON; LENTIVIRUS VECTOR; MESSENGER RNA; SHORT HAIRPIN RNA; UNCLASSIFIED DRUG; ADAR1 PROTEIN, HUMAN; RNA BINDING PROTEIN; TRANSCRIPTOME;

APOPTOSIS; ARTICLE; BREAST CANCER; BREAST CANCER CELL LINE; CELL PROLIFERATION; CHROMOSOME 1Q; CONTROLLED STUDY; CYTOKINE RESPONSE; GENE DOSAGE; GENE EXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; PRIORITY JOURNAL; RNA EDITING; RNA SEQUENCE; TRANSCRIPTOMICS; TUMOR CELL; BREAST TUMOR; FEMALE; GENETICS; MCF 7 CELL LINE; METABOLISM; MOLECULAR GENETICS; NUCLEOTIDE SEQUENCE;

ADENOSINE DEAMINASE; APOPTOSIS; BASE SEQUENCE; BREAST NEOPLASMS; CELL PROLIFERATION; FEMALE; GENE DOSAGE; HUMANS; INTERFERON TYPE I; MCF-7 CELLS; MOLECULAR SEQUENCE DATA; RNA EDITING; RNA-BINDING PROTEINS; TRANSCRIPTOME;

EID: 84944050455     PISSN: None     EISSN: 22111247     Source Type: Journal    
DOI: 10.1016/j.celrep.2015.09.032     Document Type: Article

References (58)

1. Alexandrov L.B., Nik-Zainal S., Wedge D.C., Aparicio S.A.J.R., Behjati S., Biankin A.V., Bignell G.R., Bolli N., Borg A., Børresen-Dale A.-L., et al. Signatures of mutational processes in human cancer. Nature 2013, 500:415-421. Australian Pancreatic Cancer Genome Initiative, ICGC Breast Cancer ConsortiumICGC Breast Cancer Consortium, ICGC MMML-Seq ConsortiumICGC MMML-Seq Consortium, ICGC PedBrainICGC PedBrain.
2. Athanasiadis A., Rich A., Maas S. Widespread A-to-I RNA editing of Alu-containing mRNAs in the human transcriptome. PLoS Biol. 2004, 2:e391.
3. Avesson L., Barry G. The emerging role of RNA and DNA editing in cancer. Biochim. Biophys. Acta 2014, 1845:308-316.
4. Bahn J.H., Lee J.-H., Li G., Greer C., Peng G., Xiao X. Accurate identification of A-to-I RNA editing in human by transcriptome sequencing. Genome Res. 2012, 22:142-150.
5. Bahn J.H., Ahn J., Lin X., Zhang Q., Lee J.-H., Civelek M., Xiao X. Genomic analysis of ADAR1 binding and its involvement in multiple RNA processing pathways. Nat. Commun. 2015, 6:6355.
6. Bass B.L. RNA editing by adenosine deaminases that act on RNA. Annu. Rev. Biochem. 2002, 71:817-846.
7. Bazak L., Levanon E.Y., Eisenberg E. Genome-wide analysis of Alu editability. Nucleic Acids Res. 2014, 42:6876-6884.
8. Bazak L., Haviv A., Barak M., Jacob-Hirsch J., Deng P., Zhang R., Isaacs F.J., Rechavi G., Li J.B., Eisenberg E., Levanon E.Y. A-to-I RNA editing occurs at over a hundred million genomic sites, located in a majority of human genes. Genome Res. 2014, 24:365-376.
9. Blow M.J., Grocock R.J., van Dongen S., Enright A.J., Dicks E., Futreal P.A., Wooster R., Stratton M.R. RNA editing of human microRNAs. Genome Biol. 2006, 7:R27.
10. Burns M.B., Temiz N.A., Harris R.S. Evidence for APOBEC3B mutagenesis in multiple human cancers. Nat. Genet. 2013, 45:977-983.
11. Cenci C., Barzotti R., Galeano F., Corbelli S., Rota R., Massimi L., Di Rocco C., O'Connell M.A., Gallo A. Down-regulation of RNA editing in pediatric astrocytomas: ADAR2 editing activity inhibits cell migration and proliferation. J. Biol. Chem. 2008, 283:7251-7260.
12. Chen C.X., Cho D.S., Wang Q., Lai F., Carter K.C., Nishikura K. A third member of the RNA-specific adenosine deaminase gene family, ADAR3, contains both single- and double-stranded RNA binding domains. RNA 2000, 6:755-767.
13. Chen L., Li Y., Lin C.H., Chan T.H.M., Chow R.K.K., Song Y., Liu M., Yuan Y.-F., Fu L., Kong K.L., et al. Recoding RNA editing of AZIN1 predisposes to hepatocellular carcinoma. Nat. Med. 2013, 19:209-216.
14. Curtis C., Shah S.P., Chin S.-F., Turashvili G., Rueda O.M., Dunning M.J., Speed D., Lynch A.G., Samarajiwa S., Yuan Y., et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature 2012, 486:346-352. METABRIC Group.
15. Desterro J.M.P., Keegan L.P., Lafarga M., Berciano M.T., O'Connell M., Carmo-Fonseca M. Dynamic association of RNA-editing enzymes with the nucleolus. J. Cell Sci. 2003, 116:1805-1818.
16. Efron B., Tibshirani R. On testing the significance of sets of genes. Ann. Appl. Stat. 2007, 1:107-129.
17. Han S.-W., Kim H.-P., Shin J.-Y., Jeong E.-G., Lee W.-C., Kim K.Y., Park S.Y., Lee D.-W., Won J.-K., Jeong S.-Y., et al. RNA editing in RHOQ promotes invasion potential in colorectal cancer. J. Exp. Med. 2014, 211:613-621.
18. Heale B.S.E., Keegan L.P., McGurk L., Michlewski G., Brindle J., Stanton C.M., Caceres J.F., O'Connell M.A. Editing independent effects of ADARs on the miRNA/siRNA pathways. EMBO J. 2009, 28:3145-3156.
19. Higuchi M., Maas S., Single F.N., Hartner J., Rozov A., Burnashev N., Feldmeyer D., Sprengel R., Seeburg P.H. Point mutation in an AMPA receptor gene rescues lethality in mice deficient in the RNA-editing enzyme ADAR2. Nature 2000, 406:78-81.
20. Hundley H.A., Bass B.L. ADAR editing in double-stranded UTRs and other noncoding RNA sequences. Trends Biochem. Sci. 2010, 35:377-383.
21. Jiang Q., Crews L.A., Barrett C.L., Chun H.-J., Court A.C., Isquith J.M., Zipeto M.A., Goff D.J., Minden M., Sadarangani A., et al. ADAR1 promotes malignant progenitor reprogramming in chronic myeloid leukemia. Proc. Natl. Acad. Sci. USA 2013, 110:1041-1046.
22. Ju Y.S., Kim J.-I., Kim S., Hong D., Park H., Shin J.-Y., Lee S., Lee W.-C., Kim S., Yu S.-B., et al. Extensive genomic and transcriptional diversity identified through massively parallel DNA and RNA sequencing of eighteen Korean individuals. Nat. Genet. 2011, 43:745-752.
23. Kapusta A., Kronenberg Z., Lynch V.J., Zhuo X., Ramsay L., Bourque G., Yandell M., Feschotte C. Transposable elements are major contributors to the origin, diversification, and regulation of vertebrate long noncoding RNAs. PLoS Genet. 2013, 9:e1003470.
24. Kawahara Y., Zinshteyn B., Sethupathy P., Iizasa H., Hatzigeorgiou A.G., Nishikura K. Redirection of silencing targets by adenosine-to-inosine editing of miRNAs. Science 2007, 315:1137-1140.
25. Kim D.D.Y., Kim T.T.Y., Walsh T., Kobayashi Y., Matise T.C., Buyske S., Gabriel A. Widespread RNA editing of embedded alu elements in the human transcriptome. Genome Res. 2004, 14:1719-1725.
26. Kiran A., Baranov P.V. DARNED: a DAtabase of RNa EDiting in humans. Bioinformatics 2010, 26:1772-1776.
27. Levanon E.Y., Eisenberg E., Yelin R., Nemzer S., Hallegger M., Shemesh R., Fligelman Z.Y., Shoshan A., Pollock S.R., Sztybel D., et al. Systematic identification of abundant A-to-I editing sites in the human transcriptome. Nat. Biotechnol. 2004, 22:1001-1005.
28. Li J.B., Levanon E.Y., Yoon J.-K., Aach J., Xie B., Leproust E., Zhang K., Gao Y., Church G.M. Genome-wide identification of human RNA editing sites by parallel DNA capturing and sequencing. Science 2009, 324:1210-1213.
29. Li M., Wang I.X., Li Y., Bruzel A., Richards A.L., Toung J.M., Cheung V.G. Widespread RNA and DNA sequence differences in the human transcriptome. Science 2011, 333:53-58.
30. Maas S., Patt S., Schrey M., Rich A. Underediting of glutamate receptor GluR-B mRNA in malignant gliomas. Proc. Natl. Acad. Sci. USA 2001, 98:14687-14692.
31. Mo F., Wyatt A.W., Sun Y., Brahmbhatt S., McConeghy B.J., Wu C., Wang Y., Gleave M.E., Volik S.V., Collins C.C. Systematic identification and characterization of RNA editing in prostate tumors. PLoS ONE 2014, 9:e101431.
32. Nik-Zainal S., Alexandrov L.B., Wedge D.C., Van Loo P., Greenman C.D., Raine K., Jones D., Hinton J., Marshall J., Stebbings L.A., et al. Mutational processes molding the genomes of 21 breast cancers. Cell 2012, 149:979-993. Breast Cancer Working Group of the International Cancer Genome Consortium.
33. Nishikura K. Functions and regulation of RNA editing by ADAR deaminases. Annu. Rev. Biochem. 2010, 79:321-349.
34. Ota H., Sakurai M., Gupta R., Valente L., Wulff B.-E., Ariyoshi K., Iizasa H., Davuluri R.V., Nishikura K. ADAR1 forms a complex with Dicer to promote microRNA processing and RNA-induced gene silencing. Cell 2013, 153:575-589.
35. Park E., Williams B., Wold B.J., Mortazavi A. RNA editing in the human ENCODE RNA-seq data. Genome Res. 2012, 22:1626-1633.
36. Patterson J.B., Samuel C.E. Expression and regulation by interferon of a double-stranded-RNA-specific adenosine deaminase from human cells: evidence for two forms of the deaminase. Mol. Cell. Biol. 1995, 15:5376-5388.
37. Paz N., Levanon E.Y., Amariglio N., Heimberger A.B., Ram Z., Constantini S., Barbash Z.S., Adamsky K., Safran M., Hirschberg A., et al. Altered adenosine-to-inosine RNA editing in human cancer. Genome Res. 2007, 17:1586-1595.
38. Paz-Yaacov N., Bazak L., Buchumenski I., Porath H.T., Danan-Gotthold M., Knisbacher B.A., Eisenberg E., Levanon E.Y. Elevated RNA editing activity is a major contributor to transcriptomic diversity in tumors. Cell Rep. 2015, 13:267-276. this issue.
39. Peng Z., Cheng Y., Tan B.C.-M., Kang L., Tian Z., Zhu Y., Zhang W., Liang Y., Hu X., Tan X., et al. Comprehensive analysis of RNA-Seq data reveals extensive RNA editing in a human transcriptome. Nat. Biotechnol. 2012, 30:253-260.
40. Qin Y.-R., Qiao J.-J., Chan T.H.M., Zhu Y.-H., Li F.-F., Liu H., Fei J., Li Y., Guan X.-Y., Chen L. Adenosine-to-inosine RNA editing mediated by ADARs in esophageal squamous cell carcinoma. Cancer Res. 2014, 74:840-851.
41. Ramaswami G., Lin W., Piskol R., Tan M.H., Davis C., Li J.B. Accurate identification of human Alu and non-Alu RNA editing sites. Nat. Methods 2012, 9:579-581.
42. Ramaswami G., Zhang R., Piskol R., Keegan L.P., Deng P., O'Connell M.A., Li J.B. Identifying RNA editing sites using RNA sequencing data alone. Nat. Methods 2013, 10:128-132.
43. Roberts S.A., Lawrence M.S., Klimczak L.J., Grimm S.A., Fargo D., Stojanov P., Kiezun A., Kryukov G.V., Carter S.L., Saksena G., et al. An APOBEC cytidine deaminase mutagenesis pattern is widespread in human cancers. Nat. Genet. 2013, 45:970-976.
44. Rueter S.M., Dawson T.R., Emeson R.B. Regulation of alternative splicing by RNA editing. Nature 1999, 399:75-80.
45. Salameh A., Lee A.K., Cardó-Vila M., Nunes D.N., Efstathiou E., Staquicini F.I., Dobroff A.S., Marchiò S., Navone N.M., Hosoya H., et al. PRUNE2 is a human prostate cancer suppressor regulated by the intronic long noncoding RNA PCA3. Proc. Natl. Acad. Sci. USA 2015, 112:8403-8408.
46. Sansam C.L., Wells K.S., Emeson R.B. Modulation of RNA editing by functional nucleolar sequestration of ADAR2. Proc. Natl. Acad. Sci. USA 2003, 100:14018-14023.
47. Savva Y.A., Rieder L.E., Reenan R.A. The ADAR protein family. Genome Biol. 2012, 13:252.
48. Schoggins J.W., Wilson S.J., Panis M., Murphy M.Y., Jones C.T., Bieniasz P., Rice C.M. A diverse range of gene products are effectors of the type I interferon antiviral response. Nature 2011, 472:481-485.
49. Shah S.P., Morin R.D., Khattra J., Prentice L., Pugh T., Burleigh A., Delaney A., Gelmon K., Guliany R., Senz J., et al. Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution. Nature 2009, 461:809-813.
50. Shoshan E., Mobley A.K., Braeuer R.R., Kamiya T., Huang L., Vasquez M.E., Salameh A., Lee H.J., Kim S.J., Ivan C., et al. Reduced adenosine-to-inosine miR-455-5p editing promotes melanoma growth and metastasis. Nat. Cell Biol. 2015, 17:311-321.
51. Swanton C., McGranahan N., Starrett G.J., Harris R.S. APOBEC Enzymes: Mutagenic Fuel for Cancer Evolution and Heterogeneity. Cancer Discov. 2015, 5:704-712.
52. Tomaselli S., Bonamassa B., Alisi A., Nobili V., Locatelli F., Gallo A. ADAR enzyme and miRNA story: a nucleotide that can make the difference. Int. J. Mol. Sci. 2013, 14:22796-22816.
53. Wang Q., Khillan J., Gadue P., Nishikura K. Requirement of the RNA editing deaminase ADAR1 gene for embryonic erythropoiesis. Science 2000, 290:1765-1768.
54. Wang I.X., So E., Devlin J.L., Zhao Y., Wu M., Cheung V.G. ADAR regulates RNA editing, transcript stability, and gene expression. Cell Rep. 2013, 5:849-860.
55. Witkin K.L., Hanlon S.E., Strasburger J.A., Coffin J.M., Jaffrey S.R., Howcroft T.K., Dedon P.C., Steitz J.A., Daschner P.J., Read-Connole E. RNA editing, epitranscriptomics, and processing in cancer progression. Cancer Biol. Ther. 2015, 16:21-27.
56. Yang W., Chendrimada T.P., Wang Q., Higuchi M., Seeburg P.H., Shiekhattar R., Nishikura K. Modulation of microRNA processing and expression through RNA editing by ADAR deaminases. Nat. Struct. Mol. Biol. 2006, 13:13-21.
57. Zhang L., Zhou Y., Cheng C., Cui H., Cheng L., Kong P., Wang J., Li Y., Chen W., Song B., et al. Genomic analyses reveal mutational signatures and frequently altered genes in esophageal squamous cell carcinoma. Am. J. Hum. Genet. 2015, 96:597-611.
58. Han L., Diao L., Yu S., Xu X., Li J., Zhang R., Yang Y., Werner H.M.J., Eterovic A.K., Yuan Y., et al. The genomic landscape and clinical relevance of A-to-I RNA editing in human cancers. Cancer Cell 2015, 28:515-528. this issue.